Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial.

Ye G, Chen P, Liu X, He T, Pivot X, Pan R, Zhou D, Zhu L, Zhang K, Li W, Yang S, Lin J, Cai G, Huang H

Gland Surg. 2024 03 27;13(3):374-382

Supramolecular Heterodimer Peptides Assembly for Nanoparticles Functionalization.

Mathieu C, Ghosh S, Draussin J, Gasser A, Jacquot G, Banerjee M, Gupta T, Schmutz M, Mirjolet C, Tillement O, Lux F, Klymchenko A, Donzeau M, Pivot X, Harlepp S, Detappe A

Adv Healthc Mater. 2024 03 5;:e2304250

A single chemotherapy administration induces muscle atrophy, mitochondrial alterations and apoptosis in breast cancer patients.

Mallard J, Hucteau E, Bender L, Moinard-Butot F, Rochelle E, Boutonnet L, Grandperrin A, Schott R, Pflumio C, Trensz P, Kalish-Weindling M, Charles AL, Gény B, Favret F, Pivot X, Hureau TJ, Pagano AF

J Cachexia Sarcopenia Muscle. 2024 01 6;:

Subcutaneous Administration of a Zwitterionic Chitosan-Based Hydrogel for Controlled Spatiotemporal Release of Monoclonal Antibodies.

Gréa T, Jacquot G, Durand A, Mathieu C, Gasser A, Zhu C, Banerjee M, Hucteau E, Mallard J, Lopez Navarro P, Popescu BV, Thomas E, Kryza D, Sidi-Boumedine J, Ferrauto G, Gianolio E, Fleith G, Combet J, Brun S, Erb S, Cianferani S, Charbonnière LJ, Fellmann L, Mirjolet C, David L, Tillement O, Lux F, Harlepp S, Pivot X, Detappe A

Adv Mater. 2023 12 17;:e2308738

Influence of pneumatic transportation on the stability of monoclonal antibodies.

Coliat P, Erb S, Diemer H, Karouby D, Martin T, Banerjee M, Zhu C, Demarchi M, Cianférani S, Detappe A, Pivot X

Sci Rep. 2023 12 10;13(1):21875

Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.

Pivot X, Spano JP, Espie M, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Mouri Z, Tariket F, Dupin J, Berthois A, Ionescu-Goga M, Ferhat A, Cottu P, Gligorov J

Clin Breast Cancer. 2023 06 20;:

Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial.

Pivot X, Cortés J, Lüftner D, Lyman GH, Curigliano G, Bondarenko IM, Ahn JH, Im SA, Litwiniuk M, Shparyk YV, Ho GF, Kislov NV, Wojtukiewicz M, Sarosiek T, Chae YS, Ahn JS, Jang H, Kim S, Lee J, Yoon Y

JAMA Netw Open. 2023 04 3;6(4):e235822

Exacerbated central fatigue and reduced exercise capacity in early-stage breast cancer patients treated with chemotherapy.

Hucteau E, Mallard J, Pivot X, Schott R, Pflumio C, Trensz P, Favret F, Pagano AF, Hureau TJ

Eur J Appl Physiol. 2023 03 20;:

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.

Pivot X, Manikhas AG, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Deforce F, Cox DG

BMC Cancer. 2023 01 31;23(1):112

Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy Effects.

Diringer MC, Coliat P, Mathieu C, Laurent N, Mura C, Banerjee M, Zhu C, Grabowska A, Ritchie A, Clarke P, Bernard A, Vit C, Burckel H, Noel G, Harvey P, Pivot X, Detappe A

Small. 2023 01 1;:e2205961

A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.

Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P

Breast Cancer Res Treat. 2022 12 23;:

Early skeletal muscle deconditioning and reduced exercise capacity during (neo)adjuvant chemotherapy in patients with breast cancer.

Mallard J, Hucteau E, Schott R, Trensz P, Pflumio C, Kalish-Weindling M, Favret F, Pivot X, Hureau TJ, Pagano AF

Cancer. 2022 11 17;:

A Combination of Native LC-MS Approaches for the Comprehensive Characterization of the Antibody-Drug Conjugate Trastuzumab Deruxtecan.

Deslignière E, Diemer H, Erb S, Coliat P, Pivot X, Detappe A, Hernandez-Alba O, Cianférani S

Front Biosci (Landmark Ed). 2022 10 26;27(10):290

Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab.

Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B, Chatot M, Curtit E, Mansi L, Paillard MJ, Bazan F, Chaigneau L, Dobi E, Meynard G, Vernerey D, Pivot X, Mougin F

Front Cardiovasc Med. 2022 09 23;9:1000846

Development of skeletal muscle atrophy and intermuscular adipose tissue in early breast cancer patients treated with chemotherapy.

Mallard J, Hucteau E, Bender L, Charlot A, Debrut L, Pflumio C, Trensz P, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF

Am J Physiol Cell Physiol. 2022 09 12;:

Pembrolizumab in the Treatment of Breast Cancer.

Pivot X

N Engl J Med. 2022 07 21;387(3):273-274

Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patients.

Mallard J, Hucteau E, Charles AL, Bender L, Baeza C, Pélissie M, Trensz P, Pflumio C, Kalish-Weindling M, Gény B, Schott R, Favret F, Pivot X, Hureau TJ, Pagano AF

J Cachexia Sarcopenia Muscle. 2022 Apr 4;:

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study.

Gligorov J, Pivot X, Ataseven B, De Laurentiis M, Jung KH, Manikhas A, Abdel Azim H, Gupta K, Alexandrou A, Herraez-Baranda L, Tosti N, Restuccia E

Breast. 2022 Mar 17;:

Optimal Physicochemical Properties of Antibody-Nanoparticle Conjugates for Improved Tumor Targeting.

Mittelheisser V, Coliat P, Moeglin E, Goepp L, Goetz JG, Charbonnière LJ, Pivot X, Detappe A

Adv Mater. 2022 Mar 15;:e2110305

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.

Selmani Z, Molimard C, Overs A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Mansi L, Paillard MJ, Meynard G, Viot J, Algros MP, Borg C, Feugeas JP, Pivot X, Prétet JL, Curtit E

Sci Rep. 2022 Mar 7;12(1):3617

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.

Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Fen H, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG

JAMA Oncol. 2022 Mar 3;:

Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.

Paquette B, Kalbacher E, Mercier F, Lakkis Z, Doussot A, Turco C, Caputo E, Pili-Floury S, Royer B, Mansi L, Delroeux D, Demarchi M, Pivot X, Chauffert B, Clement E, Heyd B

Ann Surg Oncol. 2022 Jan 7;:

Anti-BCMA Immuno-nanoPET Radiotracers for Improved Detection of Multiple Myeloma.

Thomas E, Mathieu C, Moreno-Gaona P, Mittelheisser V, Lux F, Tillement O, Pivot X, Ghoroghchian PP, Detappe A

Adv Healthc Mater. 2021 Oct 28;:e2101565

The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.

Twelves C, Bartsch R, Ben-Baruch NE, Borstnar S, Dirix L, Tesarova P, Timcheva C, Zhukova L, Pivot X

Clin Breast Cancer. 2021 Oct 25;:

MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer.

Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, Hurt KC, Llombart-Cussac A, Sledge GW

Clin Cancer Res. 2021 Aug 10;:

Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study.

Davie A, Cuyun Carter G, Rider A, Bailey A, Lewis K, Price G, Ostojic H, Ringeisen F, Pivot X

ESMO Open. 2021 Aug 6;6(4):100226

TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin and US-Herceptin in healthy male subjects.

Demarchi M, Coliat P, Mclendon K, Chung Shii Hii J, Feyaerts P, Ang F, Jaison L, Deforce F, Derde MP, Kim MJ, Park LS, Detappe A, Pivot X

Pharmacol Res Perspect. 2021 Aug;9(4):e00839

Incidental axillary dose delivery to axillary lymph node levels I-III by different techniques of whole-breast irradiation: a systematic literature review.

Schmitt M, Pin Y, Pflumio C, Mathelin C, Pivot X, Noel G

Strahlenther Onkol. 2021 Jul 22;:

Impact of COVID-19 and lockdown regarding blood transfusion.

Delabranche X, Kientz D, Tacquard C, Bertrand F, Roche AC, Tran Ba Loc P, Humbrecht C, Sirlin F, Pivot X, Collange O, Levy F, Oulehri W, Gachet C, Mertes PM

Transfusion. 2021 Jul 13;:

Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation.

Mertes PM, Collange O, Coliat P, Banerjee M, Diringer MC, Roche A, Delabranche X, Chaban V, Voegelin M, Bernard A, Sartori V, Laurent N, Velten M, Dhindsa N, Defuria J, Kim G, Xu ZH, Theodorou M, Huang ZR, Khalifa K, Geng B, Niyikiza C, Moyo V, Gizzi P, Villa P, Detappe A, Pivot X

J Control Release. 2021 Jun 24;:

Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.

Mamounas EP, Untch M, Mano MS, Huang CS, Geyer CE, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S

Ann Oncol. 2021 Apr 28;:

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France.

Blay JY, Boucher S, Le Vu B, Cropet C, Chabaud S, Perol D, Barranger E, Campone M, Conroy T, Coutant C, De Crevoisier R, Debreuve-Theresette A, Delord JP, Fumoleau P, Gentil J, Gomez F, Guerin O, Jaffré A, Lartigau E, Lemoine C, Mahe MA, Mahon FX, Mathieu-Daude H, Merrouche Y, Penault-Llorca F, Pivot X, Soria JC, Thomas G, Vera P, Vermeulin T, Viens P, Ychou M, Beaupere S

ESMO Open. 2021 Apr 17;6(3):100134

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.

Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S

Qual Life Res. 2021 Jan 2;:

Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.

Lunar N, Etienne-Grimaldi MC, Macaire P, Thomas F, Dalenc F, Ferrero JM, Pivot X, Milano G, Royer B, Schmitt A

Cancer Chemother Pharmacol. 2021 Jan 2;:

[Diffusion prophylactic axillary irradiation in breast cancer - Literature review].

Schmitt M, Pin Y, Pflumio C, Mathelin C, Pivot X, Noël G

Cancer Radiother. 2021 Jan 2;:

[Overall survival and survival without local recurrence in case of radiotherapy of the tumor bed of ductal carcinomas in situ of the breast: review of the literature.]

Kuntz L, Fèvre CL, Hild C, Keller A, Gharbi M, Mathelin C, Pivot X, Noël G, Antoni D

Gynecol Obstet Fertil Senol. 2021 Jan 2;:

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X

PLoS One. 2021 ;16(9):e0248222

Persistent taxane-induced neuropathy in elderly patients treated for localized breast cancer.

Pabst L, Velten M, Fischbach C, Kalish M, Pflumio C, Pivot X, Petit T

Breast J. 2020 Dec 11;:

Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size.

Bender L, Kurtz JE, Petit T, Pivot X

J Breast Cancer. 2020 Dec;23(6):672-673

Evolution in the real-world therapeutic strategies in more than 20,000 women with breast cancer having received human epidermal growth factor receptor 2-targeted treatments: Results from the french personalized reimbursement model database (2011-2018).

Cottu P, Coudert B, Perol D, Doly A, Manson J, Aujoulat O, Barletta H, Chalabi N, Samelson L, Pivot X

Eur J Cancer. 2020 Nov 8;141:209-217

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.

Fasching PA, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, Pivot X, Bianchi GV, Martin M, Chandiwana D, Lanoue B, Ridolfi A, Wang Y, Rodriguez Lorenc K, Nusch A

Breast. 2020 Sep 23;54:148-154

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries.

Davie A, Carter GC, Rider A, Pike J, Lewis K, Bailey A, Price GL, Ringeisen F, Pivot X

BMC Cancer. 2020 Sep 7;20(1):855

Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3.

Lüftner D, Lyman GH, Gonçalves J, Pivot X, Seo M

Target Oncol. 2020 Aug 3;:

Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.

Detappe A, Mathieu C, Jin C, Agius MP, Diringer MC, Tran VL, Pivot X, Lux F, Tillement O, Kufe D, Ghoroghchian PP

Int. J. Radiat. Oncol. Biol. Phys.. 2020 Jul 4;:

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.

Paracha N, Reyes A, Diéras V, Krop I, Pivot X, Urruticoechea A

Breast Cancer Res. Treat.. 2020 Feb 25;:

Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.

Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF

Front Oncol. 2020 ;10:1304

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Val Bianchi G, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G

N. Engl. J. Med.. 2019 Dec 11;:

[Biosimilars antibodies: positioning compared to originators - the experience in rheumatology and the biosimilars of trastuzumab in oncology].

Pivot X, Goupille P

Med Sci (Paris). 2019 Dec;35(12):1137-1145

Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.

Bazan F, Dobi E, Royer B, Curtit E, Mansi L, Menneveau N, Paillard MJ, Meynard G, Villanueva C, Pivot X, Chaigneau L

BMC Cancer. 2019 Nov 1;19(1):1029

Fulvestrant and palbociclib combination in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer patients.

Herrscher H, Velten M, Leblanc J, Kalish-Weindling M, Fischbach C, Exinger D, Pivot X, Petit T

Breast Cancer Res. Treat.. 2019 Oct 14;:

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.

Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A

JAMA Oncol. 2019 Sep 29;:

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, Curigliano G, Bondarenko I, Yoon YC, Kim Y, Kim C

Eur. J. Cancer. 2019 Aug 21;120:1-9

A new agent in the family of antibody-drug conjugates.

Pivot X, Petit T

Lancet Oncol.. 2019 Jun 27;:

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM,

Lancet. 2019 Jun 6;:

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.

Diéras V, Bonnefoi H, Alba E, Awada A, Coudert B, Pivot X, Gligorov J, Jager A, Zambelli S, Lindeman GJ, Charpentier E, Emmons GT, Garcia-Ribas I, Paridaens R, Verweij J

Breast Cancer Res. Treat.. 2019 Jun 6;:

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.

Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, Meyenberg C, Al-Sakaff N, Heinzmann D, Hegg R

JAMA Oncol. 2019 Apr 18;:e190339

Results of PONDx, a prospective multicenter study of the Oncotype DX breast cancer assay: Real-life utilization and decision impact in French clinical practice.

Curtit E, Vannetzel JM, Darmon JC, Roche S, Bourgeois H, Dewas S, Catala S, Mereb E, Fanget CF, Genet D, Forest AM, Bernier C, Pivot X

Breast. 2019 Jan 3;44:39-45

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project.

Cazzaniga ME, Munzone E, Bocci G, Afonso N, Gomez P, Langkjer S, Petru E, Pivot X, Sánchez Rovira P, Wysocki P, Torri V

Adv Ther. 2018 Dec 18;:

Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab.

Pivot X, Lee YJ, Lim JY, Song SJ, Kim HS, Yoon YC

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii71

Impact of BRCA status on outcomes and survival in high-risk early breast cancers.

Klajer E, Paget-Bailly S, Meynard G, Meurisse A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Montcuquet P, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Populaire C, Collonge-Rame MA, Gligorov J, Curtit E, Pivot X, Mansi L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii68

Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3.

Fasching PA, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, Wang Y, Lanoue B, Chandiwana D, Neven P

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii90

Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer.

Curtit E, Bazan F, Chaigneau L, Mouillet G, Dobi E, Mansi L, Meneveau N, Paillard MJ, Meynard G, Klajer E, Villanueva C, Montcuquet P, Pivot X, Cals L

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii117

Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients.

Cortes Castan J, Pegram M, Pivot X, Curigliano G, Lim JY, Song S, Yoon YC

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii69

Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.

Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA

Oncologist. 2018 Jul 17;:

Can we establish a hierarchy among trastuzumab biosimilar candidates?

Pivot X, Petit T

Br. J. Cancer. 2018 Jul 13;:

Milestones over the development of SB3, a trastuzumab biosimilar.

Pivot X, Bondarenko I, Petit T, Curtit E

Future Oncol. 2018 Jun 21;:

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

Jacquinot Q, Paget-Bailly S, Fumoleau P, Romieu G, Pierga JY, Espié M, Lortholary A, Nabholtz JM, Mercier CF, Pauporté I, Henriques J, Pivot X

Breast. 2018 Jun 15;41:1-7

Transmission of breast cancer polygenic risk based on single nucleotide polymorphisms.

Cox DG, Heudel PE, Henry J, Pivot X

Breast. 2018 Jun 14;41:14-18

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G

J. Clin. Oncol.. 2018 Jun 3;:JCO2018789909

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Pivot X, Im SA, Guo M, Marmé F

Breast Cancer. 2018 May;25(3):370-374

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Shparyk Y, Moiseyenko V, Bello M, Semiglazov V, Lee Y, Lim J

Eur. J. Cancer. 2018 Apr;93:19-27

Enterocolitis in Patients with Cancer Treated with Docetaxel.

Fiteni F, Paillard MJ, Orillard E, Lefebvre L, Nadjafizadeh S, Selmani Z, Benhamida S, Roland A, Baumann A, Vienot A, Houédé N, Pivot X

Anticancer Res.. 2018 04;38(4):2443-2446

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early

Pivot X, Bondarenko I, Nowecki Z, Dvorkin M, Trishkina E, Ahn JH, Vinnyk Y, Im SA, Sarosiek T, Chatterjee S, Wojtukiewicz MZ, Moiseyenko V, Shparyk Y, Bello M, Semiglazov V, Song S, Lim J

J. Clin. Oncol.. 2018 Apr 1;36(10):968-974

Fluctuating Behavior of the French Population in Cancer Screening: 5th Edition of the EDIFICE Survey.

Viguier J, Morère JF, Pivot X, Touboul C, Lhomel C, Couraud S, de La Motte Rouge T, Eisinger F

Curr Oncol Rep. 2018 Mar 5;20(Suppl 1):14

A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.

Pivot X, Deslypere JP, Park LS, Kim MJ, Lee W, Lee J

Clin Ther. 2018 Mar;40(3):396-405.e4

A new era for treatment development in HER2-positive breast cancer.

Pivot X, Cox DG

Lancet Oncol.. 2018 Feb;19(2):160-162

Emilia: use cunning to survive cancer.

Gligorov J, Richard S, Pivot X

Chin Clin Oncol. 2018 Feb;7(1):5

Why the results of adjuvant pertuzumab in HER2-positive early breast cancer has been received as a mitigate success?

Pivot X, Cox DG, Gligorov J

Chin Clin Oncol. 2018 Feb;7(1):1

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C

Oncoimmunology. 2018 ;7(5):e1424673

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.

Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A

Cancer Res Treat. 2017 Dec 28;:

Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study.

Pivot X, Verma S, Fallowfield L, Müller V, Lichinitser M, Jenkins V, Sánchez Muñoz A, Machackova Z, Osborne S, Gligorov J,

Eur. J. Cancer. 2017 Sep;86:82-90

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.

Curtit E, Pivot X, Henriques J, Paget-Bailly S, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Thomas G, Deleuze JF, Pauporté I, Romieu G, Cox DG

Breast Cancer Res.. 2017 Aug;19(1):98

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.

Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F

BMC Cancer. 2017 Jun 19;17(1):425

Factors influencing colorectal cancer screening participation rates in 2016.

Viguier J, Morere JF, Pivot X, Cortot AB, Blay JY, Touboul C, Lhomel C, Greillier L, Couraud S, Eisinger F

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii90-iii91

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A

J. Clin. Oncol.. 2017 Jun;:JCO2017737585

Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.

Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J

Eur. J. Cancer. 2017 Jun;:

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X,

Eur. J. Cancer. 2017 Jun;:

Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort.

Pivot X, Fumoleau P, Pierga JY, Delaloge S, Bonnefoi H, Bachelot T, Jouannaud C, Bourgeois H, Rios M, Soulié P, Jacquin JP, Lavau-Denes S, Kerbrat P, Cox D, Faure-Mercier C, Pauporte I, Gligorov J, Curtit E, Henriques J, Paget-Bailly S, Romieu G

Eur. J. Cancer. 2017 Jun;81:151-160

Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.

Nerich V, Saing S, Gamper EM, Holzner B, Pivot X, Viney R, Kemmler G

Breast Cancer Res. Treat.. 2017 May;:

Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.

Viot J, Bachour M, Meurisse A, Pivot X, Fiteni F

Breast. 2017 May;34:53-57

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial.

Gligorov J, Curigliano G, Müller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X

Breast. 2017 May;34:89-95

Classic cytotoxic drugs: a narrow path for regulatory approval.

Pivot X

Lancet Oncol.. 2017 Mar;18(3):279-281

First description of a double heterozygosity for BRCA1 and BRCA2 pathogenic variants in a French metastatic breast cancer patient: A case report.

Meynard G, Mansi L, Lebahar P, Villanueva C, Klajer E, Calcagno F, Vivalta A, Chaix M, Collonge-Rame MA, Populaire C, Algros MP, Colpart P, Neidich J, Pivot X, Curtit E

Oncol. Rep.. 2017 Mar;37(3):1573-1578

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort.

Pivot X, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Agostini C, Kerbrat P, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Calvo F, Renaud A, Deleuze JF, Pauporté I, Thomas G, Cox DG

NPJ Breast Cancer. 2017 ;3:4

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.

Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, Jary M, Simon P, Pivot X, Blay JY, Limat S

Clin Drug Investig. 2017 Jan;37(1):85-94

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G

PLoS ONE. 2017 ;12(5):e0175998

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.

Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P

J. Clin. Oncol.. 2017 Jan;35(2):141-148

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

Bell R, Brown J, Parmar M, Toi M, Suter T, Steger GG, Pivot X, Mackey J, Jackisch C, Dent R, Hall P, Xu N, Morales L, Provencher L, Hegg R, Vanlemmens L, Kirsch A, Schneeweiss A, Masuda N, Overkamp F, Cameron D

Ann. Oncol.. 2016 Dec;:

Prognostic and predictive indicators in early-stage breast cancer and the role of genomic profiling: Focus on the Oncotype DX(®) Breast Recurrence Score Assay.

Curtit E, Mansi L, Maisonnette-Escot Y, Sautière JL, Pivot X

Eur J Surg Oncol. 2016 Dec;:

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.

Vrdoljak E, Marschner N, Zielinski C, Gligorov J, Cortes J, Puglisi F, Aapro M, Fallowfield L, Fontana A, Inbar M, Kahan Z, Welt A, Lévy C, Brain E, Pivot X, Putzu C, González Martín A, de Ducla S, Easton V, von Minckwitz G

Ann. Oncol.. 2016 Nov;27(11):2046-2052

GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients.

Cox DG, Curtit E, Romieu G, Fumoleau P, Rios M, Bonnefoi H, Bachelot T, Soulié P, Jouannaud C, Bourgeois H, Petit T, Tennevet I, Assouline D, Mathieu MC, Jacquin JP, Lavau-Denes S, Darut-Jouve A, Ferrero JM, Tarpin C, Lévy C, Delecroix V, Trillet-Lenoir V, Cojocarasu O, Meunier J, Pierga JY, Faure-Mercier C, Blanché H, Sahbatou M, Boland A, Bacq D, Besse C, Deleuze JF, Pauporté I, Thomas G, Pivot X

Oncotarget. 2016 Nov;7(47):77358-77364

Cost-utility analyses of drug therapies in breast cancer: a systematic review.

Nerich V, Saing S, Gamper EM, Kemmler G, Daval F, Pivot X, Holzner B

Breast Cancer Res. Treat.. 2016 Oct;159(3):407-24

[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté].

Dénommé F, Kroemer M, Montcuquet P, Nallet G, Thiery-Vuillemin A, Bazan F, Mouillet G, Villanueva C, Demarchi M, Stein U, Almotlak H, Chaigneau L, Curtit E, Meneveau N, Maurina T, Dobi E, Hon TN, Cals L, Mansi L, Verlut C, Pana-Katatali H, Caubet M, Paillard MJ, Limat S, Pivot X, Nerich V

Bull Cancer. 2016 Oct;103(10):849-860

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

Calcagno F, Mouillet G, Adotevi O, Maurina T, Nguyen T, Montcuquet P, Curtit E, Kleinclauss F, Pivot X, Borg C, Thiery-Vuillemin A

Med. Oncol.. 2016 Aug;33(8):89

Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.

Pivot X, Marmé F, Koenigsberg R, Guo M, Berrak E, Wolfer A

Ann. Oncol.. 2016 Aug;27(8):1525-31

A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.

Pivot X, Curtit E, Lee YJ, Golor G, Gauliard A, Shin D, Kim Y, Kim H, Fuhr R

Clin Ther. 2016 Jul;38(7):1665-1673.e3

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.

Ferrari A, Vincent-Salomon A, Pivot X, Sertier AS, Thomas E, Tonon L, Boyault S, Mulugeta E, Treilleux I, MacGrogan G, Arnould L, Kielbassa J, Le Texier V, Blanché H, Deleuze JF, Jacquemier J, Mathieu MC, Penault-Llorca F, Bibeau F, Mariani O, Mannina C, Pierga JY, Trédan O, Bachelot T, Bonnefoi H, Romieu G, Fumoleau P, Delaloge S, Rios M, Ferrero JM, Tarpin C, Bouteille C, Calvo F, Gut IG, Gut M, Martin S, Nik-Zainal S, Stratton MR, Pauporté I, Saintigny P, Birnbaum D, Viari A, Thomas G

Nat Commun. 2016 Jul;7:12222

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Jackisch C, Hegg R, Stroyakovskiy D, Ahn JS, Melichar B, Chen SC, Kim SB, Lichinitser M, Starosławska E, Kunz G, Falcon S, Chen ST, Crepelle-Fléchais A, Heinzmann D, Shing M, Pivot X

Eur. J. Cancer. 2016 Jul;62:62-75

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O

Cancer Res.. 2016 Jul;76(14):4100-12

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR

Nature. 2016 06;534(7605):47-54

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2-positive early breast cancer.

De Cock E, Pivot X, Hauser N, Verma S, Kritikou P, Millar D, Knoop A

Cancer Med. 2016 Mar;5(3):389-97

Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.

Mansi L, Demarchi M, Bazan F, Delroeux D, Chaigneau L, Thiery-Vuillemin A, Bernhard S, Lakkis Z, Lakkis Z, Nerich V, Pivot X, Kalbacher E

Int. J. Gynecol. Cancer. 2016 Feb;26(2):261-7

[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey].

Spielmann M, Dalenc F, Pointreau Y, Azria D, Classe JM, Dromain C, Facchini T, Gonçalves A, Liegeois P, Namer M, Pivot X, Vincent-Salomon A

Bull Cancer. 2016 Feb;103(2):154-63

A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers.

Ferrari A, Sertier AS, Vincent-Salomon A, Pivot X, Pauporté I, Saintigny P, Birnbaum D, Viari A

Mol Cell Oncol. 2016 ;3(6):e1232186

Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy.

Verlut C, Mouillet G, Magnin E, Buffet-Miny J, Viennet G, Cattin F, Billon-Grand NC, Bonnet E, Servagi-Vernat S, Godard J, Billon-Grand R, Petit A, Moulin T, Cals L, Pivot X, Curtit E

Clin Med Insights Oncol. 2016 ;10:77-82

Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.

Pivot X, Aulagner G, Blay JY, Fumoleau P, Kaliski A, Sarkozy F, Limat S

Anticancer Drugs. 2015 Nov;26(10):1009-16

First description of a sporadic breast cancer in a woman with BRCA1 germline mutation.

Curtit E, Benhamo V, Gruel N, Popova T, Manie E, Cottu P, Mariani O, Stoppa-Lyonnet D, Pivot X, Stern MH, Vincent-Salomon A

Oncotarget. 2015 Nov 3;6(34):35616-24

[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].

Paillard MJ, Curtit E, Dobi E, Mansi L, Bazan F, Villanueva C, Chaigneau L, Montcuquet P, Meneveau N, Thiery-Vuillemin A, Nerich V, Pivot X

Bull Cancer. 2015 Sep;102(9):737-48

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM,

Oncologist. 2015 Aug;20(8):873-9

Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.

Pivot X, Suter T, Nabholtz JM, Pierga JY, Espie M, Lortholary A, Khayat D, Pauporte I, Romieu G, Kramar A, Fumoleau P

Eur J Cancer. 2015 Jul 7. pii: S0959-8049(15)00499-2

Breast cancer screening controversy: too much or not enough?

Pivot X, Viguier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F

Eur. J. Cancer Prev.. 2015 Jun;24 Suppl:S73-6

Cancer screening in France: third edition of the EDIFICE survey.

Viguier J, Morere JF, Touboul C, Coscas Y, Blay JY, Lhomel C, Pivot X, Eisinger F

Eur J Cancer Prev. 2015 Jun;24 New insights on cancer screening from the EDIFICE 3 survey:S68-S72.

Lung cancer risks, beliefs and healthcare access among the underprivileged.

Morere JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F

Eur J Cancer Prev. 2015 Jun;24 New insights on cancer screening from the EDIFICE 3 survey:S82-S86.

Social stratification, risk factor prevalence and cancer screening attendance.

Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morere JF

Eur J Cancer Prev. 2015 Jun;24 New insights on cancer screening from the EDIFICE 3 survey:S77-S81.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V

J Clin Oncol. 2015 May 10;33(14):1564-73

In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy?

Pivot X, Mansi L, Chaigneau L, Montcuquet P, Thiery-Vuillemin A, Bazan F, Dobi E, Sautiere JL, Rigenbach F, Algros MP, Butler S, Jamshidian F, Febbo P, Svedman C, Paget-Bailly S, Bonnetain F, Villanueva C

Oncologist. 2015 Mar 20. pii: theoncologist.2014-0198.

Prostate cancer screening: contrasting trends.

Eisinger F, Morere JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J

Cancer Causes Control. 2015 Mar 31.

Melanoma risk-takers: fathers and sons.

Eisinger F, Morere JF, Pivot X, Grange F, Lhomel C, Mortier L, Robert C, Saiag P, Sassolas B, Viguier J

J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:35-8

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.

Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X

Cancer Med. 2014 Dec;3(6):1502-11

Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study.

Jackisch C, Kim SB, Semiglazov V, Melichar B, Pivot X, Hillenbach C, Stroyakovskiy D, Lum BL, Elliott R, Weber HA, Ismael G

Ann Oncol. 2014 Nov 17. pii: mdu524.

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, Smith I, Thomssen C, Srock S, Sampayo M, Cortes J

Breast. 2014 Oct;23(5):656-62

First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimization analysis.

Nerich V, Chelly J, Montcuquet P, Chaigneau L, Villanueva C, Fiteni F, Meneveau N, Perrin S, Voidey A, Monnot T, Pivot X, Limat S

J Oncol Pharm Pract. 2014 Oct;20(5):362-8

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study.

Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L

Ann Oncol. 2014 Oct;25(10):1979-87

[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France].

Pierga JY, Delva R, Pivot X, Espie M, Dalenc F, Serin D, Veyret C, Lortholary A, Gligorov J, Joly K, Hernandez J, Hardy-Bessard AC

Bull Cancer. 2014 Sep;101(9):780-8

Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial.

Kramar A, Bachelot T, Madrange N, Pierga JY, Kerbrat P, Espie M, Fumoleau P, Pauporte I, Khayat D, Romieu G, Pivot X

Ann Oncol. 2014 Aug;25(8):1563-70

Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study.

Voidey A, Pivot X, Woronoff AS, Nallet G, Cals L, Schwetterle F, Limat S

BMC Health Serv Res. 2014 Jul;14:326

[Economic assessment of the routine use of Oncotype DX(R) assay for early breast cancer in Franche-Comte region].

Nerich V, Curtit E, Bazan F, Montcuquet P, Villanueva C, Chaigneau L, Cals L, Meneveau N, Dobi E, Altmotlak H, Algros MP, Choulot MJ, Nallet G, Limat S, Mansion S, Pivot X

Bull Cancer. 2014 Jul-Aug;101(7-8):681-9

Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Mouillet G, Nguyen Tan Hon T, Montcuquet P, Maurina T, Almotlak H, Stein U, Montange D, Foubert A, Nerich V, Pivot X, Royer B

Cancer Chemother Pharmacol. 2014 May;73(5):999-1007

Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions.

Fiteni F, Villanueva C, Bazan F, Perrin S, Chaigneau L, Dobi E, Montcuquet P, Cals L, Meneveau N, Nerich V, Limat S, Pivot X

Breast. 2014 Apr;23(2):165-9

Arthralgia and aromatase inhibitors.

Wendling D, Letho-Gyselinck H, Guillot X, Prati C, Pivot X

Joint Bone Spine. 2014 Mar;81(2):187-8

Adjuvant chemotherapy for local relapse breast cancer.

Pivot X

Lancet Oncol. 2014 Feb;15(2):125-6

Endpoints in cancer clinical trials.

Fiteni F, Westeel V, Pivot X, Borg C, Vernerey D, Bonnetain F

J Visc Surg. 2014 Feb;151(1):17-22

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.

Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratte S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S

BMC Gastroenterol. 2014 Aug 13;14:143

Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma.

Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, Kleinclauss F, Pivot X, Limat S, Thiery-Vuillemin A

Onco Targets Ther. 2014 Feb 27;7:365-74

Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Laheurte C, Mansi L, Royer B, Pivot X, Borg C, Adotevi O

J Immunother. 2014 Jan;37(1):51-4

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.

Bachelot T, Garcia-Saenz JA, Verma S, Gutierrez M, Pivot X, Kozloff MF, Prady C, Huang X, Khosravan R, Wang Z, Cesari R, Tassell V, Kern KA, Blay JY, Lluch A

BMC Cancer. 2014 Mar 7;14:166

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.

Cortes J, Baselga J, Im YH, Im SA, Pivot X, Ross G, Clark E, Knott A, Swain SM

Ann Oncol. 2013 Oct;24(10):2630-5

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

Curigliano G, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A

Breast. 2013 Oct;22(5):650-6

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R

Lancet Oncol. 2013 Sep;14(10):933-42

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, Lopez-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L

Lancet Oncol. 2013 Sep;14(10):962-70

Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?

Dobi E, Bazan F, Dufresne A, Demarchi M, Villanueva C, Chaigneau L, Montcuquet P, Ivanaj A, Sautiere JL, Maisonnette-Escot Y, Cals L, Algros MP, Woronoff AS, Pivot X

Int J Clin Oncol. 2013 Aug;18(4):607-13

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espie M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporte I, Kramar A

Lancet Oncol. 2013 Jul;14(8):741-8

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer.

Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X

Breast Cancer Res. Treat.. 2013 Jun;139(2):411-9

Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.

Curtit E, Nerich V, Mansi L, Chaigneau L, Cals L, Villanueva C, Bazan F, Montcuquet P, Meneveau N, Perrin S, Algros MP, Pivot X

Oncologist. 2013 Jun;18(6):667-74

Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.

Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N'guyen T, Vuillemin AT, Demarchi M, Dobi E, Pivot X

Target Oncol. 2013 Jun;8(2):137-43

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V

J Clin Oncol. 2013 May 10;31(14):1719-25

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortes J, Delmar PR, Scherer SJ

Br J Cancer. 2013 Mar 19;108(5):1052-60

Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.

Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS, Demarchi M, Pivot X, Limat S

J Oncol Pharm Pract. 2013 Mar;19(1):8-17

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C

Clin Colorectal Cancer. 2013 Mar;12(1):28-36

Specific anticancer treatments in the last 3 months of life: a French experience.

Viel E, Chaigneau L, Fanton E, Kalbacher E, Thiery-Vuillemnin A, Villanueva C, Dobi E, Curtit E, Almotlak H, Aubry R, Pivot X

Support Care Cancer. 2013 Feb;21(2):405-12

Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer.

Calcagno F, Nguyen T, Dobi E, Villanueva C, Curtit E, Kim S, Montcuquet P, Kleinclauss F, Pivot X, Thiery-Vuillemin A

Clin Med Insights Oncol. 2013;7:1-12

Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.

Pérol D, Provençal J, Hardy-Bessard AC, Coeffic D, Jacquin JP, Agostini C, Bachelot T, Guastalla JP, Pivot X, Martin JP, Bajard A, Ray-Coquard I

BMC Cancer. 2012 Dec;12:603

Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.

Thiery-Vuillemin A, Curtit E, Maurina T, Montange D, Succi C, Nguyen T, Kim S, Montcuquet P, Pivot X, Royer B

Ann Oncol. 2012 Nov;23(11):2992-3

First-line bevacizumab plus taxane-based chemotherapy for metastatic breast cancer: cost-minimisation analysis.

Nerich V, Bazan F, Compagnat F, Dobi E, Villanueva C, Chaigneau L, Perrin S, Voidey A, Pivot X, Limat S

Anticancer Res.. 2012 Aug;32(8):3547-52

Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.

Chaumard N, Limat S, Villanueva C, Nerich V, Fagnoni P, Bazan F, Chaigneau L, Dobi E, Cals L, Pivot X

Breast. 2012 Aug;21(4):464-7

[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O

Bull Cancer. 2012 Jul;99 Suppl 1:S57-65

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

Hardy-Bessard AC, Delva R, Pivot X, Espie M, Dalenc F, Coulon Sfairi MA, Monnier A, Serin D, Veyret C, Lortholary A, Pavlyuk M, Kockler L, Pierga JY

Bull Cancer. 2012 Jun;99(6):609-18.

Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.

Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillere B, Tartour E, Borg C, Adotevi O

Clin Cancer Res. 2012 May 15;18(10):2943-53

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J

J Clin Oncol. 2012 May 10;30(14):1594-600

Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.

Curtit E, Chaigneau L, Pauchot J, Nguyen T, Nerich V, Bazan F, Thiery-Vuillemin A, Demarchi M, Pivot X, Villanueva C

Anticancer Res.. 2012 Apr;32(4):1481-3

[KIT and KIT: from biology to clinical use].

Curtit E, Mansi L, Viel E, Dobi E, Chaigneau L, Nguyen T, Pivot X, Blay JY, Kalbacher E

Bull Cancer. 2012 Feb 1;99(2):191-7.

HER2 overexpression in metastatic breast cancer: development of therapies.

Pivot X, Jary M, Dobi E, Bazan F, Chaigneau L, Cals L, Almotlak H, Montcuquet P, Meneveau N, Villanueva C

. 2012 Jan;14(1):37-40.

Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.

Royer B, Kalbacher E, Onteniente S, Jullien V, Montange D, Piedoux S, Thiery-Vuillemin A, Delroeux D, Pili-Floury S, Guardiola E, Combe M, Muret P, Nerich V, Heyd B, Chauffert B, Kantelip JP, Pivot X

Br J Cancer. 2012 Jan 31;106(3):460-7

Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.

Pivot X, Lortholary A, Abadie-Lacourtoisie S, Mefti-Lacheraf F, Pujade-Lauraine E, Lefeuvre C, Letessier S, Morvan P, Dur C, Frimat L

Breast. 2011 Dec;20(6):510-4

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.

Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW

Eur J Cancer. 2011 Nov;47(16):2387-95

Increasing coverage rates for mammographic screening in France in older women--16 years of follow-up.

Eisinger F, Beck F, Viguier J, Blay JY, Coscas Y, Roussel C, Morere JF, Pivot X

Breast J. 2011 Nov-Dec;17(6):686-8

Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

Curtit E, Nouyrigat P, Dohollou N, Levy E, Lortholary A, Gligorov J, Facchini T, Jaubert D, Maille N, Pivot X, Grange V, Cals L

Eur J Cancer. 2011 Nov;47(16):2396-402

[Follow-up in patients with early breast cancer].

Maurina T, Chaigneau L, Bazan F, Villanueva C, Thiery-Vuillemin A, Kalbacher E, Curtit E, Cals L, N'guyen T, Pivot X

Bull Cancer. 2011 Oct 1;98(9):1091-106

Combining molecular targeted therapies: clinical experience.

Pivot X, Bedairia N, Thiery-Vuillemin A, Espie M, Marty M

Anticancer Drugs. 2011 Sep;22(8):701-10.

Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.

Thiery-Vuillemin A, Montange D, Kalbacher E, Maurina T, Nguyen T, Royer B, Bouchet S, Bazan F, Curtit E, Pivot X

Ann Oncol. 2011 Sep;22(9):2152-4.

Added value of molecular targeted agents in oncology.

Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D

Ann Oncol. 2011 Aug;22(8):1703-16

Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.

Villanueva C, Chaigneau L, Dufresne A, Thierry Vuillemin A, Stein U, Demarchi M, Bazan F, N'guyen T, Pivot X

Breast. 2011 Aug;20(4):329-33

Cabazitaxel: a novel microtubule inhibitor.

Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X

Drugs. 2011 Jul 9;71(10):1251-8

Efficacy of trabectedin in metastatic solitary fibrous tumor.

Chaigneau L, Kalbacher E, Thiery-Vuillemin A, Fagnoni-Legat C, Isambert N, Aherfi L, Pauchot J, Delroeux D, Servagi-Vernat S, Mansi L, Pivot X

Rare Tumors. 2011 Jul 11;3(3):e29

Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.

Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry-Vuillemin A, Nguyen T, Demarchi M, Bazan F, Sautiere JL, Maisonnette-Lescot Y, Ringenbach F, Bontemps P, Pivot X

Breast. 2011 Jun;20(3):284-7

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

Etienne-Grimaldi MC, Formento P, Degeorges A, Pierga JY, Delva R, Pivot X, Dalenc F, Espie M, Veyret C, Formento JL, Francoual M, Piutti M, de Cremoux P, Milano G

Br J Clin Pharmacol. 2011 Jun;71(6):921-8

Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy.

Pili-Floury S, Royer B, Bartholin F, Crumiere N, Combe M, Chalopin JM, Pivot X, Heyd B, Chauffert B, Samain E

Eur. J. Obstet. Gynecol. Reprod. Biol.. 2011 Jun;156(2):199-203

A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study.

Villanueva C, Awada A, Campone M, Machiels JP, Besse T, Magherini E, Dubin F, Semiond D, Pivot X

Eur J Cancer. 2011 May;47(7):1037-45

Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.

Curtit E, Thiery-Vuillemin A, Nguyen T, Heyd B, Pivot X, Di Martino V, Borg C

J. Clin. Oncol.. 2011 Apr;29(12):e330-2

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

Smith IE, Pierga JY, Biganzoli L, Cortes-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, Gonzalez-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI

Ann Oncol. 2011 Mar;22(3):595-602

Novel role for STAT3 in transcriptional regulation of NK immune cell targeting receptor MICA on cancer cells.

Bedel R, Thiery-Vuillemin A, Grandclement C, Balland J, Remy-Martin JP, Kantelip B, Pallandre JR, Pivot X, Ferrand C, Tiberghien P, Borg C

Cancer Res. 2011 Mar 1;71(5):1615-26

Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact.

Thiery-Vuillemin A, Llombart-Cussac A, Chaigneau L, Villanueva C, Bazan F, Montcuquet P, Maisonnette-Escot Y, Sautiere JL, Algros MP, Pivot X

Breast. 2011 Feb;20(1):46-9

Breast cancer screening in women aged 50-74 years: is there room for improvement?.

Morere JF, Pivot X, Viguier J, Blay JY, Calazel-Benque A, Coscas Y, Roussel C, Eisinger F

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S8-S12

Impact of awareness of cancer among acquaintances on cancer screening attendance.

Eisinger F, Blay JY, Morere JF, Coscas Y, Calazel-Benque A, Roussel C, Pivot X

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S36-8

Impact of general practitioners' sex and age on systematic recommendation for cancer screening.

Eisinger F, Pivot X, Coscas Y, Viguier J, Calazel-Benque A, Blay JY, Roussel C, Morere JF

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S39-41

Mammography utilization in women aged 40-49 years: the French EDIFICE survey.

Pivot X, Eisinger F, Blay JY, Coscas Y, Calazel-Benque A, Viguier J, Roussel C, Morere JF

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S16-9

Screening for prostate cancer: growth without control.

Eisinger F, Blay JY, Pivot X, Morere JF, Coscas Y, Calazel-Benque A, Roussel C, Viguier J

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S33-5

Uptake of breast cancer screening in women aged over 75 years: a controversy to come?.

Eisinger F, Viguier J, Blay JY, Morere JF, Coscas Y, Roussel C, Pivot X

Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S13-5

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.

Chan A, Miles DW, Pivot X

Ann Oncol. 2010 Dec;21(12):2305-15

Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.

Thiery-Vuillemin A, Dobi E, Nguyen T, Royer B, Montange D, Maurina T, Kalbacher E, Bazan F, Villanueva C, Demarchi M, Chaigneau L, Ivanaj A, Pivot X

Anticancer Drugs. 2010 Nov;21(10):958-62.

Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors.

Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, Westeel V, Villanueva C, Woronoff-Lemsi MC, Pivot X

Int J Med Inform. 2010 Oct;79(10):699-706.

Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.

Bidard FC, Mathiot C, Degeorges A, Etienne-Grimaldi MC, Delva R, Pivot X, Veyret C, Bergougnoux L, de Cremoux P, Milano G, Pierga JY

Ann Oncol. 2010 Sep;21(9):1765-71

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Lerzo GL, Pivot XB, de Mendoza FH, Xu BH, Vahdat L, Peck R, Mukhopadhyay P, Roche HH

Breast Cancer Res Treat. 2010 Jul;122(2):409-18

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G

J Clin Oncol. 2010 Jul 10;28(20):3239-47

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Kern KA, Martin M

Breast Cancer Res Treat. 2010 May;121(1):121-31

International network of cancer genome projects

Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusuda J, Lane DP, Laplace F, Lu YY, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang HM, Yuen MMF, Knoppers M, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SOM, Joly Y, Kato K, Kennedy KL, Nicolas P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, Biankin AV, Chabannon C, Chin L, Clement B, de Alava E, Degos F, Ferguson ML, Geary P, Hayes DN, Johns AL, Nakagawa H, Penny R, Piris MA, Sarin R, Scarpa A, Shibata T, van de Vijver M, Futreal PA, Aburatani H, Bayes M, Bowtell DDL, Campbell PJ, Estivill X, Grimmond SM, Gut I, Hirst M, Lopez-Otin C, Majumder P, Marra M, Nakagawa H, Ning ZM, Puente XS, Ruan YJ, Shibata T, Stratton MR, Stunnenberg HG, Swerdlow H, Velculescu VE, Wilson RK, Xue HH, Yang L, Spellman PT, Bader GD, Boutros PC, Campbell PJ, Flicek P, Getz G, Guigo R, Guo GW, Haussler D, Heath S, Hubbard TJ, Jiang T, Jones SM, Li QB, Lopez-Bigas N, Luo RB, Pearson JV, Puente XS, Quesada V, Raphael BJ, Sander C, Shibata T, Speed TP, Stuart JM, Teague JW, Totoki Y, Tsunoda T, Valencia A, Wheeler DA, Wu HL, Zhao SC, Zhou GY, Stein LD, Guigo R, Hubbard TJ, Joly Y, Jones SM, Lathrop M, Lopez-Bigas N, Ouellette BFF, Spellman PT, Teague JW, Thomas G, Valencia A, Yoshida T, Kennedy KL, Axton M, Dyke SOM, Futreal PA, Gunter C, Guyer M, McPherson JD, Miller LJ, Ozenberger B, Kasprzyk A, Zhang JJ, Haider SA, Wang JX, Yung CK, Cross A, Liang Y, Gnaneshan S, Guberman J, Hsu J, Bobrow M, Chalmers DRC, Hasel KW, Joly Y, Kaan TSH, Kennedy KL, Knoppers BM, Lowrance WW, Masui T, Nicolas P, Rial-Sebbag E, Rodriguez LL, Vergely C, Yoshida T, Grimmond SM, Biankin AV, Bowtell DDL, Cloonan N, Defazio A, Eshleman JR, Etemadmoghadam D, Gardiner BA, Kench JG, Scarpa A, Sutherland RL, Tempero MA, Waddell NJ, Wilson PJ, Gallinger S, Tsao MS, Shaw PA, Petersen GM, Mukhopadhyay D, Chin L, DePinho RA, Thayer S, Muthuswamy L, Shazand K, Beck T, Sam M, Timms L, Ballin V, Lu YY, Ji JF, Zhang XQ, Chen F, Hu XD, Zhou GY, Yang Q, Tian G, Zhang LH, Xing XF, Li XH, Zhu ZG, Yu YY, Yu J, Yang HM, Lathrop M, Tost J, Brennan P, Holcatova I, Zaridze D, Brazma A, Egevad L, Prokhortchouk E, Banks RE, Uhlen M, Cambon-Thomsen A, Viksna J, Ponten F, Skryabin K, Stratton MR, Futreal PA, Birney E, Borg A, Borresen-Dale AL, Caldas C, Foekens JA, Martin S, Reis-Filho JS, Richardson AL, Sotiriou C, Stunnenberg HG, Thomas G, van de Vijver M, van't Veer L, Birnbaum D, Blanche H, Boucher P, Boyault S, Chabannon C, Gut I, Masson-Jacquemier JD, Lathrop M, Pauporte I, Pivot X, Vincent-Salomon A, Tabone E, Theillet C, Thomas G, Tost J, Treilleux I, Bioulac-Sage P, Clement B, Decaens T, Degos F, Franco D, Gut I, Gut M, Heath S, Lathrop M, Samuel D, Thomas G, Zucman-Rossi J, Lichter P, Eils R, Brors B, Korbel JO, Korshunov A, Landgraf P, Lehrach H, Pfister S, Radlwimmer B, Reifenberger G, Taylor MD, von Kalle C, Majumder PP, Sarin R, Scarpa A, Pederzoli P, Lawlor RT, Delledonne M, Bardelli A, Biankin AV, Grimmond SM, Gress T, Klimstra D, Zamboni G, Shibata T, Nakamura Y, Nakagawa H, Kusuda J, Tsunoda T, Miyano S, Aburatani H, Kato K, Fujimoto A, Yoshida T, Campo E, Lopez-Otin C, Estivill X, Guigo R, de Sanjose S, Piris MA, Montserrat E, Gonzalez-Diaz M, Puente XS, Jares P, Valencia A, Himmelbaue H, Quesada V, Bea S, Stratton MR, Futreal PA, Campbell PJ, Vincent-Salomon A, Richardson AL, Reis-Filho JS, van de Vijver M, Thomas G, Masson-Jacquemier JD, Aparicio S, Borg A, Borresen-Dale AL, Caldas C, Foekens JA, Stunnenberg HG, van't Veer L, Easton DF, Spellman PT, Martin S, Chin L, Collins FS, Compton CC, Ferguson ML, Getz G, Gunter C, Guyer M, Hayes DN, Lander ES, Ozenberger B, Penny R, Peterson J, Sander C, Speed TP, Spellman PT, Wheeler DA, Wilson RK, Chin L, Knoppers BM, Lander ES, Lichter P, Stratton MR, Bobrow M, Burke W, Collins FS, DePinho RA, Easton DF, Futreal PA, Green AR, Guyer M, Hamilton SR, Hubbard TJ, Kallioniemi OP, Kennedy KL, Ley TJ, Liu ET, Lu YY, Majumder P, Marra M, Ozenberger B, Peterson J, Schafer AJ, Spellman PT, Stunnenberg HG, Wainwright BJ, Wilson RK, Yang HM

Nature. 2010 Apr 15;464(7291):993-8.

Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study.

Guardiola E, Chauffert B, Delroeux D, Royer B, Heyd B, Combe M, Benoit L, Causeret S, Demarchi M, Magnin G, Mayer F, Tixier H, Pivot X

Anticancer Drugs. 2010 Mar;21(3):320-5.

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.

Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X

Br J Cancer. 2010 Mar 2;102(5):827-32

Safety profile of new anticancer drugs.

Mansi L, Thiery-Vuillemin A, Nguyen T, Bazan F, Calcagno F, Rocquain J, Demarchi M, Villanueva C, Maurina T, Pivot X

Expert Opin Drug Saf. 2010 Mar;9(2):301-17.

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fatima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA

J Clin Oncol. 2010 Feb 20;28(6):976-83

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Pivot XB, Li RK, Thomas ES, Chung HC, Fein LE, Chan VF, Jassem J, de Mendoza FH, Mukhopadyay P, Roche HH

Eur J Cancer. 2009 Nov;45(17):2940-6

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M

J Clin Oncol. 2009 Nov 20;27(33):5538-46

Response Rates A Valuable Signal of Promising Activity?

Pivot X, Thierry-Vuillemin A, Villanueva C, Bazan F

Cancer J. 2009 Sep-Oct;15(5):361-5.

How to strengthen the French breast cancer clinical research: the example of the PHARE trial

Pauporte I, Faure C, Pivot X

Oncologie. 2009 Jun;11(6):348-52

Ixabepilone: a new active chemotherapy in the treatment of breast cancer.

Villanueva C, Vuillemin AT, Demarchi M, Bazan F, Chaigneau L, Pivot X

Womens Health (Lond Engl). 2009 Mar;5(2):115-21.

Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.

Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M, Stein U, Royer B, Chauffert B, Pivot X

World J Surg Oncol. 2009 Feb 9;7:14.

Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration Development of a Limited Sampling Strategy for Toxicity Risk Assessment

Royer B, Jullien V, Guardiola E, Heyd B, Chauffert B, Kantelip JP, Pivot X

Clin Pharmacokinet. 2009;48(3):169-80

Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation.

Pallandre JR, Krzewski K, Bedel R, Ryffel B, Caignard A, Rohrlich PS, Pivot X, Tiberghien P, Zitvogel L, Strominger JL, Borg C

Blood. 2008 Dec 1;112(12):4420-4

Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.

Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, Demarchi M, Borg C, Fagnoni-Legat C, Kantelip JP, Pivot X

Ann Oncol. 2008 Nov;19(11):1980-1.

[Edifice program: analysis of screening exam practices for cancer in France]

Blay JY, Eisinger F, Rixe O, Calazel-Benque A, Morere JF, Cals L, Coscas Y, Dolbeault S, Namer M, Serin D, Roussel C, Pivot X

Bull Cancer. 2008 Nov;95(11):1067-73.

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients.

Pivot X, Koralewski P, Hidalgo JL, Chan A, Goncalves A, Schwartsmann G, Assadourian S, Lotz JP

Ann Oncol. 2008 Sep;19(9):1547-52

Report of a young man with three successive curable cancers.

Pavic M, Flechon A, Pivot X, Schell M, Droz JP

Eur J Intern Med. 2008 Jul;19(5):387-8

Predictors of re-excision for positive or close margins in breast-conservation therapy for pT1 tumors.

Ramanah R, Pivot X, Sautiere JL, Maillet R, Riethmuller D

Am J Surg. 2008 Jun;195(6):770-4

Cancer screening in France: subjects' and physicians' attitudes.

Eisinger F, Blay JY, Morere JF, Rixe O, Calazel-Benque A, Cals L, Coscas Y, Dolbeault S, Namer M, Serin D, Roussel C, Pivot X

Cancer Causes Control. 2008 May;19(4):431-4

Squamous cell carcinoma of the head and neck: ESMO clinical Recommendations for diagnosis, treatment and follow-up.

Pivot X, Felip E,

Ann. Oncol.. 2008 May;19 Suppl 2:ii79-80

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

Marty M, Pivot X

Eur J Cancer. 2008 May;44(7):912-20

Ixabepilone, a novel epothilone analog in the treatment of breast cancer.

Pivot X, Villanueva C, Chaigneau L, Nguyen T, Demarchi M, Maurina T, Stein U, Borg C

Expert Opin Investig Drugs. 2008 Apr;17(4):593-9.

Anticancer therapy in patients with porphyrias: evidence today.

Thiery-Vuillemin A, Chaigneau L, Meaux-Ruault N, Villanueva C, N'guyen T, Maurina T, Stein U, Lorgis V, Demarchi M, Pivot X

Expert Opin Drug Saf. 2008 Mar;7(2):159-65.

Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.

Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, Kantelip JP, Chauffert B, Heyd B, Pivot X

Cancer Chemother Pharmacol. 2008 Mar;61(3):415-21

A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.

Viel E, Demarchi MF, Chaigneau L, Nguyen T, Legat C, Stein U, Thiery-Vuillemin A, Limat S, Pivot X, Borg C

Am J Clin Oncol. 2008 Feb;31(1):89-94.

Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue

Villanueva C, Dufresne A, Pivot X, Viel E

Bull Cancer. 2008 Feb;95(2):197-204.

Breast cancer screening in France: results of the EDIFICE survey.

Pivot X, Rixe O, Morere J, Coscas Y, Cals L, Namer M, Serin D, Dolbeault S, Eisinger F, Roussel C, Blay J

Int J Med Sci. 2008 May 24;5(3):106-12.

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer.

Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, De Gramont A

Breast Cancer Res Treat. 2008 Jan;107(2):275-9

Impact of organised programs on colorectal cancer screening.

Eisinger F, Cals L, Calazel-Benque A, Blay JY, Coscas Y, Dolbeault S, Namer M, Pivot X, Rixe O, Serin D, Roussel C, Morere JF

BMC Cancer. 2008 Apr 15;8:104.

Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer.

Dufresne A, Pivot X, Tournigand C, Facchini T, Alweeg T, Chaigneau L, De Gramont A

Int J Med Sci. 2008 May 5;5(2):100-5.

Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Pivot X, Felip E

Ann Oncol. 2008;19 Suppl. 2:79-80

Role of STAT3 in CD4(+)CD25(+)FOXP3(+) regulatory lymphocyte generation: Implications in graft-versus-host disease and antitumor immunity

Pallandre JR, Brillard E, Crehange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling XA, Tiberghien P, Borg C

J Immunol. 2007 Dec 1;179(11):7593-604.

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.

Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu BH, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roche HH

J Clin Oncol. 2007 Nov 20;25(33):5210-7

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

Massard C, Voigt JJ, Laplanche A, Culine S, Lortholary A, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Fizazi K

Br J Cancer. 2007 Oct 8;97(7):857-61

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.

Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, Viens P, Cai C, Mullaney B, Peck R, Hortobagyi GN

J Clin Oncol. 2007 Aug 10;25(23):3407-14

Pemetrexed development in oncology

Chaigneau L, Villanueva C, Thierry-Vuillemin A, Legat-Fagnoni C, N'Guyen T, Maurina T, Lorgis V, Pivot X

Bull Cancer. 2007;94 Spec No Actualites:S142-8.

Efficacy and safety of ixabepilone, a novel epothilone analogue

Pivot X, Dufresne A, Villanueva C

Clin Breast Cancer. 2007 Apr;7(7):543-9.

Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Pivot X, Villanueva C

Ann Oncol. 2007 Apr;18 Suppl 2:ii65-6.

Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4(+)CD25(-) T lymphocytes

Brillard E, Pallandre JR, Chalmers D, Ryffel B, Radlovic A, Seilles E, Rohrlich PS, Pivot X, Tiberghien P, Saas P, Borg C

Exp Hematol. 2007 Mar;35(3):416-25.

Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by Xavier Pivot.

Pivot X

Drugs. 2007;67(12):1800-1.

ESMO activities and resources for medical training

Blay JY, Pivot X

Oncologie. 2007 Jan;9(1):37-40

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.

Fagnoni P, Limat S, Chaigneau L, Guardiola E, Briaud S, Schmitt B, Merrouche Y, Pivot X, Woronoff-Lemsi MC

Support Care Cancer. 2006 Oct;14(10):1030-7

[Appropriate cytotoxic drug usages in solid tumors: conformity to official labelling and level of scientific evidence]

Grangeasse L, Coudert B, Pivot X, Fumoleau P, Depierre A, Chauffert B, Huichard S, Woronoff-Lemsi MC, Arveux P, Limat S

Bull Cancer. 2006 Oct 1;93(10):1047-54.

[Induction chemotherapy in patients with head and neck cancer].

Chaigneau L, Guardiola E, N'Guyen T, Dufresne A, Stein U, Villanueva C, Thiery-Vuillemin A, Lorchel F, Pivot X

Bull Cancer. 2006 Jul 1;93(7):677-82.

Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.

Limat S, Bracco-Nolin CH, Legat-Fagnoni C, Chaigneau L, Stein U, Huchet B, Pivot X, Woronoff-Lemsi MC

Eur J Health Econ. 2006 Jun;7(2):107-13.

[Cost effectiveness of Ligasure Precise versus surgical clips during axillary nodal dissection for breast cancer].

Magri K, Bertrand V, Sautiere JL, Pivot X, Riethmuller D, Maillet R, Marinkovic Z

J Gynecol Obstet Biol Reprod (Paris). 2006 Jun;35(4):341-7.

Is there still a role for triple endoscopy as part of staging for head and neck cancer?

Guardiola E, Chaigneau L, Villanueva C, Pivot X

Curr Opin Otolaryngol Head Neck Surg. 2006 Apr;14(2):85-8.

Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.

Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X

Anticancer Drugs. 2005 Oct;16(9):1009-16.

Molecularly targeted agents: their promise as cancer chemopreventive interventions.

Thiery-Vuillemin A, Nguyen T, Pivot X, Spano JP, Dufresnne A, Soria JC

Eur J Cancer. 2005 Sep;41(13):2003-15.

Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer.

Pivot X, Magne N, Guardiola E, Poissonnet G, Dassonville O, Francoual M, Formento JL, Bensadoun RJ, Demard F, Schneider M, Milano G

Oral Oncol. 2005 Mar;41(3):320-7.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck (SCCHN).

Pivot X, Kataja VV, Jelic S

Ann Oncol. 2005;16 Suppl 1:i62-3.

Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.

Urien S, Brain E, Bugat R, Pivot X, Lochon I, Van ML, Vauzelle F, Lokiec F

Cancer Chemother Pharmacol. 2005 Jan;55(1):55-60

Is routine triple endoscopy for head and neck carcinoma patients necessary in light of a negative chest computed tomography scan?

Guardiola E, Pivot X, Dassonville O, Poissonnet G, Marcy PY, Otto J, Poudenx M, Francois E, Bensadoun RJ, Thyss A, Demard F, Schneider M

Cancer. 2004 Nov;101(9):2028-33

Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.

Guardiola E, Peyrade F, Chaigneau L, Cupissol D, Tchiknavorian X, Bompas E, Madroszyk A, Ronchin P, Schneider M, Bleuze JP, Blay JY, Pivot X

Eur. J. Cancer. 2004 Sep;40(14):2071-6

Liver metastases from head and neck squamous cell carcinomas: radiological and biological features.

Marcy PY, Magné N, Bailet C, Pivot X, Dassonville O, Poissonnet G, Demard F

Onkologie. 2004 Apr;27(2):157-60

Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients.

Pivot X, Chamorey E, Guardiola E, Magné N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G

Ann. Oncol.. 2003 Oct;14(10):1578-86

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

Culine S, Lortholary A, Voigt JJ, Bugat R, Théodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Négrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K,

J. Clin. Oncol.. 2003 Sep;21(18):3479-82

Results of randomised phase II studies comparing S16020 with methotrexate in patients with recurrent head and neck cancer.

Pivot X, Awada A, Gedouin D, Kerger J, Rolland F, Cupissol D, Caponigro F, Comella G, Lopez-Pousa JJ, Guardiola E, Giroux B, Gerard B, Schneider M

Ann Oncol. 2003 Mar;14(3):373-7.

Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer.

Pivot X, Wadler S, Kelly C, Ruxer R, Tortochaux J, Stern J, Belpomme D, Humblet Y, Domenge C, Clendeninn N, Johnston A, Penning C, Schneider M

Ann Oncol. 2001 Nov;12(11):1595-9.

Pr PIVOT Xavier

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Recherche

Publications